EXSCIENTIA
Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY). This expanded collaboration has the potential to add to the Bristol Myers Squibb drug pipeline whilst enhancing Exscientia’s portfolio of shared assets. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology & immunology. The agreement includes up to $50 million in upfront funding, up to $125 million in near to mid-term potential milestones, and additional clinical, regulatory and commercial payments that take the potential value of the deal beyond $1.2 billion. Exscientia will also receive tiered royalties on net sales of any marketed drug products resulting from the collaboration.
This expanded collaboration builds upon Exscientia’s existing collaboration with Bristol Myers Squibb that was initiated in 2019 with Celgene prior to Celgene’s acquisition by Bristol Myers Squibb. Exscientia will take responsibility for AI-design and experimental work necessary to discover drug candidates associated with this collaboration for Bristol Myers Squibb. Molecules will be designed using Exscientia’s AI-driven drug discovery platform, which delivers optimized compounds fulfilling complex design goals faster and more effectively than traditional drug discovery.
Andrew Hopkins, CEO of Exscientia, commented, “We are proud that Bristol Myers Squibb wants to build on our work together with this expanded collaboration and believe it speaks to the strength and promise of Exscientia’s AI technologies and drug discovery expertise. We’re excited to work with such an experienced collaborator as Bristol Myers Squibb to develop the best possible medicines for patients .”
Rupert Vessey, President of Research & Early Development at Bristol Myers Squibb said, “We have been pleased with Exscientia’s work in tackling a number of distinct projects for Bristol Myers Squibb. Exscientia’s application of AI technologies is proving capable of generating best-in-class molecules while also reducing discovery times. Rapid discovery of molecules that can enter the clinic in a timely manner could positively impact our work in discovering treatments for areas of unmet medical need ”
Exscientia has already built a strong track record for its drug discovery platform, being the first company to advance AI-designed small molecule drug candidates into clinical studies. In addition to Bristol Myers Squibb, Exscientia has previously entered collaborations with major pharmaceutical companies including Bayer, Sanofi, and Dainippon Sumitomo, multiple emerging biotech companies and the Gates Foundation, demonstrating Exscientia’s reputation as the collaborator of choice for high-value AI-driven drug discovery. The company currently has more than a dozen partnered or wholly owned drugs in development. Exscientia recently secured a $525 million Series D investment, led by Softbank, to further fund expansion of its technology capabilities and proprietary drug pipeline.
About Exscientia
Exscientia’s AI centric, end-to-end drug discovery platform is set to revolutionise the process invention of new drugs, designing therapeutics for areas of high unmet medical need that could positively impact patients, with timelines that are many years shorter than industry standards. As a clinical stage company, Exscientia is the first to advance AI-designed small molecules into a clinical setting, demonstrating the potential of AI to transform the pharmaceutical industry.
Drug design is precision engineering at the molecular scale. To transform the industry, Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently re-apply enhanced knowledge through iterations of design. Because Exscientia’s AI systems learn more rapidly and effectively than human-led efforts, candidate molecules satisfying complex therapeutic requirements are discovered with revolutionary efficiency.
For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005180/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting indgår samarbejde med virksomheden Vivaldi31.10.2025 15:43:00 CET | Pressemeddelelse
Andersen Consulting annoncerer en samarbejdsaftale med Vivaldi, der er et globalt konsulentfirma inden for forretnings- og brandstrategi, hvilket styrker organisationens løsninger inden for strategi og forretningstransformation. Vivaldi, der blev oprettet i 1999, er kendt for sin tilgang, som forener brand, forretning og teknologi for at hjælpe kunder med at bevare deres position som markedsledere. Med aktiviteter i USA, Europa og Latinamerika samarbejder Vivaldi med nogle af verdens førende virksomheder om at styrke markedspositioner, accelerere innovation og udvikle kundecentrerede forretningsmodeller. I en tid, der er præget af hurtig forandring, drevet af kunstig intelligens, platformdynamikker og kontinuerlig fornyelse, hjælper Vivaldi sine kunder med at gentænke, hvordan forretningsværdi skabes og udnyttes. Virksomhedens tværfaglige teams kombinerer dyb indsigt i forbrugeradfærd og markedsudvikling med strategisk, kreativ og finansiel ekspertise for at levere skræddersyede løsnin
Andersen Consulting styrker sin platform gennem samarbejde med threon31.10.2025 15:35:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for forretningstransformation og digital transformation via en samarbejdsaftale med threon, der er et belgisk konsulentfirma, som er kendt for at levere pragmatisk og helhedsorienteret støtte til strategiimplementering. I mere end 20 år har threon været en vigtig rådgiver for organisationer, der ønsker at omsætte store idéer til reel forretningsmæssig effekt. Virksomheden er specialiseret i strategisk porteføljestyring, digital transformation og ledelsestræning for at hjælpe ledere med at omsætte visioner til konkret handling. threons unikke tilgang kombinerer projektlevering, udvikling af medarbejdere og intelligente softwareløsninger, hvilket giver teams mulighed for at levere hurtigere, opskalere i det rette tempo og opnå varige resultater. Tom Dedecker, CEO for threon, udtalte: "Vi skaber fokus og ro i organisationer, hvilket gør det muligt at træffe hurtigere beslutninger og gennemføre en bæredygtig transformation, der er forankre
SBC Medical to Announce Q3 2025 Financial Results on November 14 and Hold Earnings Call on November 1731.10.2025 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it will release its Q3 2025 financial results on Friday, November 14, 2025, before the U.S. market opens. The Company will hold a Earnings Call on Monday, November 17, 2025 at 5:00 p.m. Eastern Time to discuss the financial results and take questions live. Please register in advance for the conference using the link provided below. https://edge.media-server.com/mmc/p/e2znwqtx It will automatically direct you to the registration page for “SBC Q3 2025 Financial Results Presentation.” Please follow the steps to enter your registration details and click “Submit.” Upon registration, you will be able to access the dedicated conference call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as pas
Motive Brings Seamless eSIM Activation to Luxury European Automotive Brand in Latin America31.10.2025 11:00:00 CET | Press release
Motive, a global leader in connected device lifecycle management and automation, has announced a landmark partnership with a leading operator in Central and South America, bringing seamless and secure mobile connectivity to a luxury European automotive brand’s vehicles in Mexico. The solution—powered by Motive's Entitlement Server—enables the carrier’s subscribers to link their mobile identities directly to their vehicles using embedded SIM (eSIM) technology leveraging GSMA’s mobile connectivity standards. This automotive-first for the Latin America region allows drivers to activate their mobile subscription upon entering a vehicle, delivering a personalized, connected experience on par with their smartphones. Whether for entertainment, navigation, or communication services, users benefit from uninterrupted access to their mobile services with enhanced security and privacy. "This deployment showcases the power of intelligent entitlement and provisioning," said Francisco Viana, VP Sales
Hanshow and Unide Partner to Advance Store Modernization under the “Plan Unide 2.0” Strategy31.10.2025 02:45:00 CET | Press release
Hanshow, a global leader in digital retail solutions, has announced a strategic collaboration with Unide Corporativa, one of Spain’s most established food retail cooperatives, to advance store digitalization and operational efficiency under its new strategic roadmap “Plan Unide 2.0” (2025–2028). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030921658/en/ Founded over 90 years ago, Unide unites hundreds of independent grocery retailers across Spain under a cooperative model built on proximity, freshness, and community service. With Plan Unide 2.0, the cooperative aims to strengthen competitiveness through member business development, store modernization, and new store openings—a roadmap to ensure sustainable growth in an evolving retail landscape. Unide faces operational challenges common to cooperative retail: manual paper label updates, inconsistent pricing, and limited promotional agility across its network. Meanwhile,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom